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Bilge Debelec-Butuner1,2, Nursah Ertunc1 and Kemal Sami Korkmaz1*Abstract
The oxidative stress response is a cellular defense mechanism that protects cells from oxidative damage and cancer
development. The exact molecular mechanism by which reactive oxygen species (ROS) contribute to DNA damage
and increase genome instability in prostate cancer merits further investigation. Here, we aimed to determine the
effects of NKX3.1 loss on antioxidant defense in response to acute and chronic inflammation in an in vitro model.
Oxidative stress-induced DNA damage resulted in increased H2AX(S139) phosphorylation (a hallmark of DNA damage),
along with the degradation of the androgen receptor (AR), p53 and NKX3.1, upon treatment with conditioned medium
(CM) obtained from activated macrophages or H2O2. Furthermore, the expression and stability of SIRT1 were increased
by CM treatment but not by H2O2 treatment, although the level of ATM
(S1981) phosphorylation was not changed
compared with controls. Moreover, the deregulated antioxidant response resulted in upregulation of the pro-oxidant
QSCN6 and the antioxidant GPX2 and downregulation of the antioxidant GPX3 after CM treatment. Consistently, the
intracellular ROS level increased after chronic treatment, leading to a dose-dependent increase in the ability of LNCaP
cells to tolerate oxidative damage. These data suggest that the inflammatory microenvironment is a major factor
contributing to DNA damage and the deregulation of the oxidative stress response, which may be the underlying
cause of the increased genetic heterogeneity during prostate tumor progression.
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Oxidative stress contributes to the initiation, promotion
and progression of carcinogenesis. Excessive levels of re-
active oxygen species (ROS) are generated by exposure
to oxidative stress and cause sustained DNA damage.
DNA damage occurs during the initiation step of car-
cinogenesis, and most likely results in abnormal gene
expression. Because ROS accumulation results in a sub-
sequent failure of signal transduction at the promotion
step, the cells undergo a loss of genomic fidelity during
the progression step [1]. Notably, ROS are generated in
excess amounts during chronic inflammation, and ROS-
mediated DNA damage alters the genetic composition.* Correspondence: ks_korkmaz@yahoo.com
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article, unless otherwise stated.This damage may promote oncogenic transformation,
which occurs when genes encoding essential factors in-
volved in DNA repair, apoptosis and cell cycle regulation
are affected [2]. Others have shown that ROS contribute
to carcinogenesis by activating signaling pathways that
regulate cellular proliferation, angiogenesis and metastasis
[3-5]. ROS serve as secondary messengers for the activa-
tion of key transcription factors in response to pro-
inflammatory cytokines, and they also regulate the
transcription of genes involved in inflammatory responses
[6,7]. Additionally, a number of protein kinase pathways,
such as the MAPK pathway, are activated by oxidative sig-
nals during inflammation and inflammatory diseases.
These pathways synergistically contribute to the activation
of cytokine release, and combined with the loss of adhe-
sion and the release of angiogenic factors, they may even-
tually contribute to cellular proliferation, differentiationd Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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multiple signal transduction pathways, such as those me-
diated by TNFα [8] and p53. These two pathways can acti-
vate each other, as DNA damage caused by TNFα-induced
ROS directly induces cell cycle and/or apoptosis regula-
tion by p53 [9]. In addition to the ability of cells to trigger
proliferation in response to sustained ROS production at
low levels, excess ROS generation or the accumulation of
ROS may induce cell death depending on the ROS con-
centration and cell type [4]. Although ROS can induce
apoptosis or necrosis depending on the oxidative level [3],
the appropriate cellular responses to ROS production are
critical events and may protect the cell from sustained oxi-
dative damage and support cell survival.
To reduce the oxidative damage caused by ROS, the
antioxidant response system is activated through several
constitutive and inducible detoxification mechanisms,
including the expression of enzymes such as glutathione
peroxidases (GPx), catalase, superoxide dismutases (SODs),
peroxiredoxins (PRDXs), glutathione-S-transferases (GSTs),
NADP (H) quinone oxidoreductase (NQO1), epoxide hy-
drolase, heme oxygenase (HO-1), UDP-glucuronosyl trans-
ferases (UGTs), and gamma-glutamylcysteine synthetase.
The upregulated expression of these enzymes exhibits a
distinct cellular defense to protect cells from oxidative
damage and cancer development [7,10].
In addition to the mechanisms that regulate ROS, cell
proliferation is controlled by stress-sensing molecules
such as Sirtuin 1 (SIRT1), an NAD-dependent deacety-
lase that responds to the levels of redox pairs NAD+/
NADH and NADP+/NADPH. Under oxidative conditions,
SIRT1 deacetylates a number of transcription factors, in-
cluding p53, NBS1 and FOXO, which subsequently con-
tribute to cellular metabolic responses, such as cell cycle
regulation and DNA damage [7,11,12]. Therefore, SIRT1
has been linked to tumor cell survival by deregulating
apoptosis and promoting senescence. Particularly, in pros-
tate cancer, the deacetylation of AR by SIRT1 represses
androgen-induced AR transcription and contributes to
AR-induced tumorigenesis [13].
NKX3.1 is an androgen-regulated gene that encodes a
homeobox protein with a tumor suppressor function in
prostate cells [14,15]. The AR response is ubiquitous in
prostate tumors, and NKX3.1 is upregulated by andro-
gens; in contrast, NKX3.1 loss has been reported in
prostate tumors [16]. Furthermore, the functional loss of
NKX3.1 expression upon cytokine exposure has been re-
ported in previous studies of the inflammatory micro-
environment [17,18], strengthening its tumor suppressor
role in prostate carcinogenesis. The pro-inflammatory
cytokines TNFα and IL-1β induce the C-terminal phos-
phorylation of NKX3.1 by casein kinase 2 (CK2), result-
ing in a shortened half-life [17,18]. Additionally, loss of
NKX3.1 expression in pathogen E. coli infected prostatelobes in mice has been shown to be correlated with re-
duced AR expression [19]. It was previously reported
that the loss of NKX3.1 expression was related not only
to the loss of AR transactivating function [17,18] but
also to high ROS level upon cytokine exposure, particu-
larly TNFα [17]. Concurrently, the loss of p53 expression
was also observed in the inflammatory microenvironment,
promoted the progression of prostate cancer, perhaps cor-
relating with increased oxidative stress. This effect was
partially restored by suppressing AKT and MDM2 phos-
phorylations, leading to p53 degradation [18].
In this study, we aimed to identify the role of cytokine-
induced NKX3.1 loss in the deregulation of the antioxi-
dant defense during acute and chronic exposure to both
cytokines and ROS. Therefore, the effect of antioxidant
treatment on the inflammation- and/or oxidative stress-
induced degradation of NKX3.1, AR and p53 was ana-
lyzed. Cultures of the prostate cancer cell line LNCaP
were exposed to conditioned medium (CM) with adjusted
amounts of pro-inflammatory cytokines (TNFα) for 24 h
for acute treatment and for 2 weeks for chronic treatment.
Cells were also chronically treated with H2O2 for 2 weeks
to compare the effects of pro-inflammatory cytokines and
ROS exposure.
Materials and methods
Macrophage differentiation and conditioned media (CM)
collection
The U937 monocyte cell line was cultured in RPMI
1640 medium including 10% FBS (fetal bovine serum) at
37°C with 5% CO2. To achieve macrophage differenti-
ation and cytokine production, cells (8×105) were seeded
into 75-cm2 culture flasks 2 h prior to treatment. Next,
PMA was added at a final concentration of 16 nM for
16 h, and the adherent clusters (differentiated mono-
cytes) were maintained. The cells were washed twice be-
fore the addition of 20 ml of fresh medium, and the cells
were then allowed to rest for 3 h. Then, lipopolysacchar-
ide (LPS) was added at a final concentration of 10 ng/ml
to induce cytokine secretion. The cells were incubated
for an additional 24 h, and the supernatant (conditioned
medium - CM) was collected and filtered (using a 0.22-μm
filter) for further use. To ensure that the CM was cell-free,
diluted CM was cultured in an empty flask (25 cm2) for
one week and analyzed.
Measurement of cytokines in CM
Before feeding the LNCaP cells with the collected CM
(cell-free), the TNFα (Invitrogen, USA) levels were ana-
lyzed using an ELISA according to the manufacturer’s
instructions. Because cytokine exposure is a major com-
ponent of the inflammatory microenvironment, the
times (0, 2, 4, 6, 12 and 24 h) and doses (62.5, 125, 250
or 500 pg/ml TNFα-containing conditioned medium)
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ported in our previous study [18]. TNFα was chosen as
a measure of the CM concentration, which was adjusted
by diluting the CM with normal medium before applica-
tion to the LNCaP cells. As a result, the concentrations
of macrophage-secreted cytokines were adjusted and
maintained at picogram levels. In our studies, the effect-
ive concentration of TNFα was 400 times less than the
concentration of recombinant TNFα (rTNFα) (sigma,
UK) reported in other studies [17-19].
Cell culture and treatments
LNCaP cells were obtained from the American Type Cul-
ture Collection (ATCC, Manassas, VA, USA) and were
propagated as recommended using RPMI 1640 medium
supplemented with 10% FBS, L-glutamine (2 mM), peni-
cillin (100 U/ml) and streptomycin (100 μg/ml) at 37°C
with 5% CO2. For the acute exposures, the CM (62, 125,
and 250 pg/ml of TNFα) treatments were performed for
24 h; for the chronic exposures, the CM treatments con-
tinued for 2 weeks, and lower doses (50 and 100 pg/ml of
TNFα) were used. TNFα concentrations were adjusted by
diluting the CM using RPMI 1640 medium as described
previously [18]. A chronic oxidative condition was also in-
duced by treating the cells with 50, 100 or 200 μM H2O2
for 2 weeks for comparison of the effects of cytokine ex-
posure and oxidative stress.
Transfections
The NKX3.1 open reading frame was amplified (using the
primers F: GGATCCATGCTCAGGGTTCCGGAGCCG
and R: GAATTCGGTTGTCACCTGAGCTGGCATTA)
and cloned into the pcDNA4/HisMax-TOPO vector (Invi-
trogen, USA) according to the manufacturer’s instructions
to obtain HM-NKX3.1 and the HM-vector constructs.
Then, transfections were performed using the Fugene HD
reagent (Roche, Germany) for 24 h. The cells were incu-
bated for an additional 18 to 42 h, as appropriate.
The siNKX3.1 and siAR transfections were performed
as recommended by the supplier (Dharmacon). Briefly,
4×105 cells were seeded into 6-cm plates, and the
medium was changed (w/o antibiotics). A transfection
mix was prepared by adding 6 μl of Dharmafect II (tube
1) and 200 pmol of siNKX3.1, siAR or scrambled siRNA
(tube 2) into 94 μl of transfection medium (w/o antibi-
otics and serum). After incubation for 5 min at RT, the
tubes were mixed and incubated for 15 min at RT and
then added onto the cells dropwise. The transfected cells
were incubated for an additional 24 h before harvesting.
Antibodies
The following antibodies were purchased from the man-
ufacturers: AR (Millipore, USA), p53, pH2AX(S139) and
pATM(S1981) (Abcam, UK), GAPDH (Ambion, UK), β-actin and SIRT1 (Sigma, UK), Caspase-3 (R&D, UK), and
β-tubulin (ABM, UK). The NKX3.1 custom antibody was
a gift from Prof. Dr. F. Saatcioglu (University of Oslo). The
HRP-conjugated anti-mouse and anti-rabbit (Amersham,
UK) and the AlexaFluor 488- and 594-conjugated second-
ary antibodies (Invitrogen, USA) were purchased and used
as recommended by the manufacturers.
DCFH assay
LNCaP cells (8×103) were seeded into 96-well plates,
and the transfections were carried out on the following
day. Two days later, the cells were incubated with
DCFH-DA (2′ 7′- dichlorodihydrofluorescein diacetate,
Molecular Probes, 10 μM) for 30 min at 37°C. Next, the
treatments were performed following gentle washes
using phenol red-free medium. Finally, the fluorescence
intensity was measured every 20 min for up to 3 h using
a Fluoroscan fluorometer (Thermo Science, USA).
Protein extraction and western blotting
For protein extraction, LNCaP cells were lysed using a
modified RIPA buffer (10 mM Tris-Cl (pH: 8.0), 1% Triton
X-100, 0.1% SDS, 0.1% Na deoxycholate, 1 mM EDTA,
1 mM EGTA, 140 mM NaCl) containing protease and
phosphatase inhibitors. Then, the concentrations were de-
termined using the BCA assay (Sigma, UK). SDS-PAGE
and western blots were performed under standard condi-
tions with 50 μg of protein lysate per lane. The proteins
were separated on 10-12% gels and transferred to PVDF
membranes (Amersham, UK) using a wet transfer blotter.
The PVDF membrane was blocked with 5% dry milk in
TBS-T (Tris-Buffered-Saline solution containing 0.1%
Tween 20). The primary and secondary antibody incuba-
tions were performed in TBS-T containing 0.5% dry milk
or 5% BSA at RT for 1 h or at 4°C o/n. The membranes
were developed using the ECL prime reagent (Amersham,
UK) for 5 min and were photographed using Kodak X-Ray
films in a dark room.
Real-time cell proliferation assay
The Xcelligence proliferation assay platform was used for
real-time measurements. Briefly, the LNCaP cells (8×103)
were transfected with an HM vector and HM-NKX3.1
(24 h), seeded into 96-well plates (E-plates, Roche GmbH,
Germany) and cultured for 24 h. The treatments were per-
formed as described, and the proliferation rate and mor-
phological changes were monitored. Impedance values
were collected every 10 min for 48 h.
cDNA synthesis
Total RNA was isolated from the LNCaP cells using
the RNeasy kit (Qiagen, CA, USA), and the yield was
calculated using absorbance readings at 260/280 nm.
Then, cDNA synthesis was performed using a cDNA
Figure 1 Antioxidant LNAC treatment restores AR, NKX3.1 and
p53 expression levels. In LNCaP cells, the expression levels that
were reduced by treatment with A. CM (including 125 and 250 pg/ml
of TNFα) and B. H2O2 (250 μM) for 24 h were partially restored back to
control expression levels by the antioxidant LNAC (10 mM) treatment.
LNAC was applied to the cells 1 h prior to the addition of CM or H2O2.
C. AR depletion together with CM treatment reduced the NKX3.1 level.
CM: conditioned media.
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manufacturer.
Real time PCR
To study the expression of specific genes, quantitative
RT-PCR was performed using a SYBR Green PCR kit
and the LC480 PCR system (Roche, Germany). The rela-
tive abundance of each transcript was calculated using the
comparative cycle threshold (CT) method with GAPDH
as an invariant control. The following primers were used:
GPX2_F: CAGTCTCAAGTATGTCCGT, GPX2_R: AGGC
TCAATGTTGATGGT; GPX3_F: CTTGCACCATTCGG
TCT, GPX3_R: CGGACATACTTGAGGGTAG; PRDX6_F:
TAGTGTGATGGTCCTTCCAAC, PRDX6_R: AGCGGA
GGTATTTCTTGC; QSCN6_F: GAGGCTACGTGCACT
ACT, QSCN6_R: CTGCAAGGCGAGCATTGA; ENOX2_
F: CTGAACGTGAAGCACTG, ENOX2_R: ATCAAGAC
GGTGCAAGTAG; SOD1_F: TGTACCAGTGCAGGTCC,









Student’s t test was applied to determine the statistical
significance between pairs where necessary.
Results and discussion
NKX3.1, AR, and p53 degradation is restored by LNAC
treatment
To determine whether inflammatory cytokine or oxida-
tive exposure is the major factor in ROS-dependent re-
duction of AR, NKX3.1 and p53 protein levels, LNCaP
cells were treated with CM or H2O2 with or without the
antioxidant, N-Acetyl-L-cysteine (LNAC). The CM treat-
ments resulted in the degradation of AR, p53 and NKX3.1
in a dose-dependent manner, which is consistent with our
previous studies [18]. Interestingly, LNAC treatment par-
tially restored AR, but not NKX3.1, at low (125 pg/ml of
TNFα) concentrations of CM (Figure 1A). Because the
antioxidant treatment could not significantly change the
expression level of NKX3.1 and AR under inflammatory
conditions (CM treatment), cytokine exposure was sug-
gested as the major cause of NKX3.1 and AR depletion.
Nevertheless, AR and NKX3.1 degradation in the presence
of H2O2 were almost completely restored back to basal
levels by LNAC (Figure 1B), suggesting that there is clear
crosstalk between ROS and cytokine signaling. Also, the
p53 level was slightly increased by LNAC in the control
cells, and it was completely restored back to the basalexpression level at lower doses of CM (Figure 1A). Because
LNAC also enhanced the p53 level after H2O2 treatment
(Figure 1B), these results implied that p53 degradation
under inflammatory conditions was dependent upon the
increased ROS levels. Furthermore, we performed AR si-
lencing together with CM treatment in LNCaP cells, and
the results showed that the reduced NKX3.1 level was a
consequence of the synergetic effects of repression of AR
transactivation due to AR depletion and CM-mediated
proteasomal degradation (Figure 1C).
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limit oxidative damage
NKX3.1 is an important androgen-regulated transcrip-
tion factor in prostate and testis tissues. Here, CM
(250 pg/ml of TNFα) treatments were performed for 3, 6
and 24 h. The results indicate that NKX3.1 loss was cor-
related with antioxidant responsive gene expression in
LNCAP cells. We found that the expression of the pro-
oxidants Quiescin Q6 (QSCN6) and Ecto-NOX disulfide
thiol exchanger 2 (ENOX2) was increased by 2.7 and
1.3-fold relative to the controls, respectively. The anti-
oxidant glutathione peroxidase-2 (GPX2) was upregu-
lated 6.2-fold, and glutathione peroxidase-3 (GPX3) and
peroxiredoxin-6 (PRDX6) were downregulated 12.5- and
2.4-fold, respectively. Further, the antioxidant superoxide
dismutase-1 (SOD1) was downregulated 1.5-fold, whereas
superoxide dismutase-2 (SOD2) was upregulated 2.3-fold
after 24 h of CM treatment (Figure 2A). Because an ap-
proximately 30-fold reduction of NKX3.1 was observed
upon CM exposure, these data support the finding that
the loss of NKX3.1 could be related not only to cytokineFigure 2 Depleting NKX3.1 results in alterations in the expression of
course (3, 6 and 24 h) of CM exposure influences gene expression in LNCa
anti-oxidant enzymes, respectively. B. The changes in gene expression caus
CM treatment (250 pg/ml of TNFα for 24 h) in LNCaP cells. C. Histogram pl
upon NKX3.1 depletion that did not correlate with CM exposure. Red and g
Western blot confirms the depleted NKX3.1 protein level in comparison toexposure [17] but also to the loss of the androgen
receptor.
To investigate whether the loss of the oxidative stress
response in prostate cancer cells was related to the loss
of NKX3.1 expression or androgen signaling during in-
flammation, NKX3.1 was depleted by transfection with
siRNA for 48 h, and the mRNA levels of specific genes
were quantified. The analyzed genes were classified into
two groups. The first group consisted of the genes whose
expression was dose-dependently affected by treatment
with CM. This group included GPX2 and QSCN6, which
were upregulated by 5.6-fold and 1.9-fold, respectively,
and PX3, PRDX6 and SOD1, which were downregulated
by 2.4-fold, 2-fold and 2.5-fold, respectively (Figure 2B
and C). The second group consisted of the genes whose
expression was influenced by NKX3.1 depletion but not
by CM treatment (Figure 2B and C). This group included
ENOX2, which was upregulated by 3.7-fold compared to
the control, and SOD2, which was downregulated by 2.5-
fold. NKX3.1 depletion was confirmed by a 4.8-fold
decrease in the mRNA level (Figure 2). In addition, thegenes involved in the regulation of oxidative stress. A. Time
P cells. Pink and green colors indicate the gene expression of pro- and
ed by NKX3.1 depletion correlate with the changes that occurred after
ot demonstrates the genes that underwent changes in expression
reen bars indicate upregulation and downregulation, respectively.
B-actin expression due to NKX3.1 silencing.
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mented with ectopic NKX3.1 expression, and its role in
oxidative regulation was investigated. Ectopic NKX3.1 ex-
pression significantly increased the expression of GPX2
(3.7 to 5.1) and SOD2 (3.8 to 5.9) upon CM exposure
(Figure 3A). These data suggested that the restored
NKX3.1 expression back to its normal levels enhanced the
antioxidant response in the inflammatory microenviron-
ment. Moreover, the intracellular ROS level was examined
using the DCFH assay following the treatment of NKX3.1-
overexpressing LNCaP cells with H2O2 (50 and 100 μM).
Upon H2O2 treatment, a significant reduction in the ROS
level was observed not only in control cells with basal
NKX3.1 expression but also in cells with ectopic NKX3.1
expression (Figure 3B). The data demonstrate that LNCaP
cells require NKX3.1 expression for regulation of the anti-
oxidant response during inflammation in the prostate.
SIRT1 leads to oxidative stress resistance in the
inflammatory microenvironment
The accumulation of damage to DNA, proteins and
lipids is characterized by an increase in intracellularFigure 3 Overexpression of NKX3.1 leads to the suppression of
oxidative stress. A. The CM (250 pg/ml of TNFα for 24 h)-mediated
increase in GPX2 and SOD2 expression is upregulated upon NKX3.1
overexpression in LNCaP cells. B. The H2O2-induced intracellular ROS
level is suppressed by NKX3.1. Control and NKX3.1-expressing
constructs (pcDNA4-HM) were transfected into the cells 24 h prior to
H2O2 treatment, p < 0.001.oxidative stress levels due to a progressive decrease of
ROS scavenging [18,20]. Several lines of evidence indi-
cate that the loss of oxidative tolerance is age dependent
and associated with DNA damage as well as metabolic
deregulation [21]. The SIRT1-mediated increase in oxi-
dative stress tolerance and the concurrent activation of
the p53-mediated DNA damage response were corre-
lated with an extended lifespan in mouse models. A de-
crease in p53 activity reduces the essential role of p53 in
tumor prevention in older animals [22]. Thus, a dra-
matic increase in the frequency of cancer provides a
likely explanation for the correlation between tumori-
genesis and the accumulation of DNA mutations [23,24]
that might be related to a decreased stress tolerance and
increased genetic heterogeneity during multiple inflam-
matory exposures over a lifetime.
p53 is found to be completely lost or mutated at a
high frequency in advanced prostate cancer [25], but
many other tumor suppressors also contribute to the
regulation of cell proliferation and apoptosis. An in-
crease in the stability of p53 by hyperacetylation via sev-
eral acetylases activates p53 to trigger apoptosis and cell
cycle arrest. Conversely, the deacetylation of p53 induced
by sustained SIRT1 expression enhances the destruction
of p53 through ubiquitin-mediated proteasomal degrad-
ation [26]. This work suggests that the activation of SIRT1
(via decreased metabolic events) unexpectedly increases
the genetic heterogeneity in the inflammatory micro-
environment, where the DNA damage response may not
be activated. Because high expression of SIRT1 is a com-
mon and relevant pathologic event in prostate cancer
[27], we examined DNA damage, the subsequent acti-
vation of SIRT1 and the DNA damage response. We
observed that oxidative stress strongly increased the
γ-H2AX(S139) levels (a hallmark of DNA damage) upon
treatment with CM and H2O2, concurrent to the increase
in SIRT1 expression/stability upon CM treatment, al-
though the γ-H2AX(S139) levels were not increased upon
treatment with H2O2. However, the antioxidant (LNAC)
restored SIRT1 expression to its basal level in cells ex-
posed to high concentrations of CM (Figure 4A). Because
the CM-induced DNA damage cannot be restored by
LNAC, the γ-H2AX(S139) level remained high upon CM
treatment and was partially restored upon H2O2 treat-
ment. CM treatment results in a significant amount of
DNA damage, suggesting that the level of DNA damage is
high in the inflammatory microenvironment but not in
more highly oxidative conditions, in which the putative re-
sponsive pathways remain to be elucidated. On the other
hand, because the relative SIRT1 mRNA level (Figure 4B)
correlated with the SIRT1 protein level, we hypothesized
that SIRT1 is upregulated under inflammatory conditions
and that additional control mechanisms affect protein sta-
bility. These data suggest that SIRT1 is an important
Figure 4 Inflammation results in sustained oxidative damage to DNA. A. The levels of the DNA damage marker γ-H2AX(S139) and the
metabolic regulator SIRT1 are remarkably affected by treatment with CM and H2O2 in the absence of LNAC. B. SIRT1 mRNA expression in LNCaP
cells is altered by treatment with CM (including 125 and 250 pg/ml of TNFα) and 250 μM H2O2 with and without 10 mM LNAC. C. Caspase 3 and
p-ATM(S1981) levels remain lower in the treated cells in comparison to controls, indicating that the cells failed to activate apoptosis and the DNA
damage response upon oxidative DNA damage. LPS (10 ng/ml) treatment was used as positive control for caspase-3 cleavage and activation.
D. LNCaP cells were exposed to CM (including 50 and 100 pg/ml of TNFα) and H2O2 (50, 100 and 200 μM) for 2 weeks. Chronic exposure to CM,
but not H2O2, results in the loss of NKX3.1. E. Similar to the acute treatments (24 h), chronic CM exposure (100 pg/ml of TNFα) also results in
increases in QSCN6 and GPX2 expression but a decrease in GPX3 expression in LNCaP cells. Red bars represent upregulation, green bars represent
downregulation. F. Chronic CM exposure, but not treatment with H2O2, results in an increase in the intracellular ROS level; chronic exposure to
H2O2 does not affect the level of ROS in LNCaP cells. The ROS level was measured using a DCFH-DA assay with four replicates.
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dative level under oxidative stress tolerance conditions.
Furthermore, because the SIRT1 level was increased in
the cells treated with CM, we elucidated the DNA dam-
age response activation by examining the p-ATM(S1981)
level. Interestingly, we found that ATM(S1981) phosphor-
ylation was not significantly increased upon CM treat-
ment. LNAC only induced p-ATM(S1981) in control cells
and not after CM exposure, suggesting that the reducedoxidative stress levels might trigger a cell cycle progression
and DNA damage response, presumably via SIRT1-
mediated p53 and NBS1 activations respectively. However,
this hypothesis requires further investigation. We also ex-
amined whether apoptosis was induced in response to
DNA damage, and found that the ATM-mediated re-
sponse upon CM exposure did not generate caspase-3
cleavage in LNCaP cells, either with or without LNAC
treatment (Figure 4B). These data demonstrate that
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to proliferate with damaged DNA, resulting in genetic het-
erogeneity. However, this proliferation was suppressed by
the metabolic activity sensor and NAD+-dependent deace-
tylase SIRT1, which slows down the cell cycle through the
deacetylation of functional p53 to allow time for DNA
damage repair. This process requires the presence of func-
tional NKX3.1 in prostate cells [28,29]. This mechanism
might result in oxidative stress tolerance and is commonly
observed in cancer progression.
Loss of NKX3.1 under conditions of chronic inflammation
leads to an abrogated antioxidant response
Chronic inflammation with sustained oxidative stress is
well known to promote carcinogenesis [2]. To mimic
chronic inflammation in vitro, we fed LNCaP cells withFigure 5 ROS-mediated changes are partially restored upon
NKX3.1 expression or LNAC treatment. A. LNAC treatment and
B. NKX3.1 overexpression remarkably suppresses cellular proliferation
when LNCaP cells are treated with CM (including 62 and 125 pg/ml
of TNFα). LNAC (10 mM) or NKX3.1 overexpression restores the
CM-mediated suppression in cell proliferation. HM-NKX3.1 was
transfected into the cells 24 h before CM treatment. HM: Hismax
control vector, NKX: HM-NKX3.1 transfection. The Xcelligence real-time
cell proliferation assay system was used to evaluate cell proliferation.
The blue arrows indicate when the treatments were performed.CM (50 and 100 pg/ml of TNFα) or normal media or
H2O2 (50, 100 and 200 μM) for a 2-week period. First,
we analyzed the proteasomal degradation of NKX3.1,
which correlated with exposure to increasing concentra-
tions of CM (Figure 4C) but not with H2O2 treatments,
confirming that cytokines are the major cause of NKX3.1
degradation. Secondly, we investigated the expression of
antioxidant genes and detected the upregulation of the
pro-oxidant QSCN6 (3.8-fold), marginal upregulation of
the antioxidant GPX2 (increase 1.3-fold) and downregula-
tion of GPX3 (2.5-fold) after CM (100 pg/ml of TNFα)
treatment (Figure 4D). These alterations may be due to
the chronic exposure to inflammatory cytokines, which
might be sufficient to maintain cell survival. Surprisingly,
treatment of cells with H2O2 did not result in significant
changes in the expression of antioxidant response factors
(data not shown). We also measured the intracellular ROS
levels after the chronic treatments to gain insight into the
changes in the oxidative conditions within the cells.
Chronic CM exposure dose dependently correlated with
an increase in the ROS level, but chronic H2O2 exposure
maintained the ROS level close to the basal concentration
(Figure 4E). These data suggest that inflammatory cyto-
kine release is the major factor underlying the deregulated
antioxidant response and sustained oxidative damage in
prostate cells. Additionally, we found that NKX3.1 loss
caused by CM exposure inversely correlated with an in-
creased ROS level. When the NKX3.1 level remained
stable after H2O2 exposure, there was no change in the
ROS level. Thus, these data suggest that the increasedFigure 6 Scheme representing the mechanism of cancer
development as a result of the loss of the NKX3.1 protein in
inflammation.
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consequence of NKX3.1 loss.
NKX3.1 suppresses the proliferation enhanced by the
inflammatory microenvironment
To investigate the influence of NKX3.1 loss on cell sur-
vival, we examined cellular proliferation. In a real-time set-
ting for 18 h, we observed that the rate of LNCaP cell
proliferation increased after (62 and 125 pg/ml of TNFα
including) CM treatment. The proliferation rate was sup-
pressed with either LNAC treatment (Figure 5A) or when
NKX3.1 was expressed ectopically (Figure 5B). These data
demonstrate that NKX3.1 deregulates cell proliferation in-
duced by the inflammatory microenvironment by function-
ing similarly to LNAC in the response to oxidative stress.
Conclusions
Overall, the inflammatory microenvironment is the major
factor leading to sustained DNA damage in LNCaP cells,
and the loss of NKX3.1 is an important contributing event.
Therefore, the use of antioxidants might have a limited,
but important ability to suppress the associated tumori-
genic alterations, particularly in prostatic inflammation
related cancer development. Upon chronic exposure of
LNCaP cells to CM to mimic inflammation-like condi-
tions, the loss of NKX3.1 leads to the deregulation of oxi-
dative stress scavengers and contributes to increased
DNA damage, eventually the prostate tumor progression
(Figure 6). The inflammatory microenvironment model
proposed here represents a novel approach for investigat-
ing the molecular and cellular alterations in cells in vitro,
closely resembling animal studies [19].
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